
We are pleased to announce that the Center for Antiviral Medicines and Pandemic Preparedness (CAMPP) was selected as one of the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
CAMPP has been awarded $67 million for three years, with potential renewal for two additional years. The AViDD Centers' program is one of the U.S. government’s responses to the COVID-19 pandemic and is aimed at the near-term development of drugs against viruses with high pandemic potential — including coronaviruses, filoviruses (such as Ebola virus), flaviviruses (yellow fever virus, dengue virus, Zika virus), paramyxoviruses, bunyaviruses, and togaviruses.
Read the press releases from Scripps Research and NIH.
The Center for Antiviral Medicines & Pandemic Preparedness (CAMPP) will draw upon world class drug discovery infrastructure embedded in an academic setting, as well as a network of expert virologists, chemists, pharmacologists, structural and computational biologists, and significant prior investments in global health drug discovery, to generate a more substantial pool of antiviral lead series and candidate drugs with the potential to address the immediate threat of SARS-CoV-2 and provide antiviral drug candidates that might quickly pivot to address future outbreaks or pandemics of other viruses of pandemic concern, including other coronaviruses, flaviviruses, and filoviruses.
Join us on our mission to build better treatments for the current pandemic,
and ensure we are prepared for the next one.

Research Projects
The Center comprises six Projects that are supported by five Cores.
Project 1
Novel CoV Protease Inhibitors
Arnab Chatterjee | Calibr
Gaetano T. Montelione | Rensselaer Polytechnic Institute
Shaun Stauffer | Cleveland Clinic


Project 2
Novel CoV Polymerase Inhibitors
Christopher F. Basler | Icahn School of Medicine at Mount Sinai
Gustavo Palacios | Icahn School of Medicine at Mount Sinai
Matthias Götte | University of Alberta
Christopher Parker | Scripps Research
Ben Cravatt | Scripps Research
Case McNamara | Calibr
Matthew Frieman | University of Maryland School of Medicine
Anil Gupta | Calibr
Project 3
Next-generation Antivirals Against
SARS-CoV-2 Druggable Proteins
Michael Farzan | UF Scripps Biomedical Research
Sumit Chanda | Scripps Research
Suganya Selvarajah | Prosetta Biosciences
John Guatelli | University of California San Diego
Stanley Opella | University of California San Diego
Stuart Lipton | Scripps Research
Hyeryun Choe | Scripps Research


Project 4
Antivirals Against Undruggable SARS-CoV-2 Targets
Adolfo García-Sastre | Icahn School of Medicine at Mount Sinai
Sumit Chanda | Scripps Research
Matthew D. Disney | UF Scripps Biomedical Research
Jose Gallego | Catholic University of Valencia
Hong Moulton | Oregon State University
Matthew J. Evans | Icahn School of Medicine at Mount Sinai
Beatriz Fontoura | UT Southwestern
Luis Martinez-Sobrido | Texas Biomedical Research Institute
Christopher Parker | Scripps Research
Ben Cravatt | Scripps Research
Project 5
Development of Antivirals to Flaviviruses
Sara Cherry | University of Pennsylvania
Sumit Chanda | Scripps Research
Michael S. Diamond | Washington University School of Medicine


Project 6
Development of Therapeutics
for Hemorrhagic Fever Viruses
Juan Carlos de la Torre | Scripps Research
Christopher F. Basler | Icahn School of Medicine at Mount Sinai
Jae Jung | Cleveland Clinic
Robert Davey | Boston University
Gaya Amarasinghe | Washington University School of Medicine
Christopher Parker | Scripps Research
Suganya Selvarajah | Prosetta Biosciences
Sumit Chanda | Scripps Research
Luis Martinez-Sobrido | Texas Biomedical Research Institute
Core A
High-throughput Screening Core
Kristen Johnson | Calibr


Core B
Medicinal Chemistry Core
Anil Gupta | Calibr
Core C
Pharmacology & Formulation Core
Sean Joseph | Calibr
Victor Chi | Calibr


Core D
Organoid & Animal Model Core
John Teijaro | Scripps Research
Matthew Frieman | University of Maryland School of Medicine
Jae Jung | Cleveland Clinic
Thomas Rogers | University of California San Diego
Kanta Subbarao | University of Melbourne
Core E
Structural Biology and Computational Modeling Core
Ian Wilson | Scripps Research
Andrew Ward | Scripps Research
Stefano Forli | Scripps Research


Industry & Foundation Partners
Prosetta Biosciences
HitGen
Schrödinger
Johnson & Johnson
Intrepid Alliance
Gilead
Atomwise
Bill & Melinda Gates Foundation
Wellcome Trust